|
1
|
Jameson JL and Longo DL: Precision
medicine-personalized, problematic, and promising. N Engl J Med.
372:2229–2234. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Moscow JA, Fojo T and Schilsky RL: The
evidence framework for precision cancer medicine. Nat Rev Clin
Oncol. 15:183–192. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tannock IF and Hickman JA: Limits to
personalized cancer medicine. N Engl J Med. 375:1289–1294.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Le Tourneau C, Delord JP, Gonçalves A,
Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA,
Mauborgne C, et al: Molecularly targeted therapy based on tumour
molecular profiling versus conventional therapy for advanced cancer
(SHIVA): A multicentre, open-label, proof-of-concept, randomised,
controlled phase 2 trial. Lancet Oncol. 16:1324–1334.
2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Trédan O, Wang Q, Pissaloux D, Cassier P,
de la Fouchardière A, Fayette J, Desseigne F, Ray-Coquard I, de la
Fouchardière C, Frappaz D, et al: Molecular screening program to
select molecular-based recommended therapies for metastatic cancer
patients: Analysis from the ProfiLER trial. Ann Oncol. 30:757–765.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Massard C, Michiels S, Ferté C, Deley MC,
Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S,
Ammari S, et al: High-throughput genomics and clinical outcome in
hard-to-treat advanced cancers: Results of the MOSCATO 01 trial.
Cancer Discov. 7:586–595. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Mock A, Heilig CE, Kreutzfeldt S,
Huebschmann D, Heining C, Schröck E, Brors B, Stenzinger A, Jäger
D, Schlenk R, et al: Community-driven development of a modified
progression-free survival ratio for precision oncology. ESMO Open.
4(583)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Rodon J, Soria JC, Berger R, Miller WH,
Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña
I, et al: Genomic and transcriptomic profiling expands precision
cancer medicine: The WINTHER trial. Nat Med. 25:751–758.
2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Huang M, Shen A, Ding J and Geng M:
Molecularly targeted cancer therapy: Some lessons from the past
decade. Trends Pharmacol Sci. 35:41–50. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Schmitt MW, Loeb LA and Salk JJ: The
influence of subclonal resistance mutations on targeted cancer
therapy. Nat Rev Clin Oncol. 13:335–347. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Pishvaian MJ, Blais EM, Brody JR, Lyons E,
DeArbeloa P, Hendifar A, Mikhail S, Chung V, Sahai V, Sohal DP, et
al: Overall survival in patients with pancreatic cancer receiving
matched therapies following molecular profiling: A retrospective
analysis of the know your tumor registry trial. Lancet Oncol.
21:508–518. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Verlingue L, Malka D, Allorant A, Massard
C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, et al:
Precision medicine for patients with advanced biliary tract
cancers: An effective strategy within the prospective MOSCATO-01
trial. Eur J Cancer. 87:122–130. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
National Human Genome Research Institute
(NHGRI): The cost of sequencing a human genome. https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost.
Accessed December 6, 2020.
|
|
14
|
Schwarze K, Buchanan J, Taylor JC and
Wordsworth S: Are whole-exome and whole-genome sequencing
approaches cost-effective? A systematic review of the literature.
Genet Med. 20:1122–1130. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Van Nimwegen KJM, Van Soest RA, Veltman
JA, Nelen MR, Van Der Wilt GJ, Vissers LELM and Grutters JPC: Is
the 1000 genome as near as we think? A cost analysis of
next-generation sequencing. Clin Chem. 62:1458–1464.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Pagès A, Foulon S, Zou Z, Lacroix L,
Lemare F, de Baère T, Massard C, Soria JC and Bonastre J: The cost
of molecular-guided therapy in oncology: A prospective cost study
alongside the MOSCATO trial. Genet Med. 19:683–690. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Morganti S, Tarantino P, Ferraro E,
D'Amico P, Viale G, Trapani D, Duso BA and Curigliano G: Role of
next-generation sequencing technologies in personalized medicine.
In: P5 eHealth: An Agenda for the Health Technologies of the
Future. Pravettoni G and Triberti S (eds). Springer International
Publishing, Cham, pp125-154, 2020.
|
|
18
|
Phillips KA, Deverka PA, Marshall DA,
Wordsworth S, Regier DA, Christensen KD and Buchanan J:
Methodological issues in assessing the economic value of
next-generation sequencing tests: Many challenges and not enough
solutions. Value Health. 21:1033–1042. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tan AC, Lai GGY, Tan GS, Poon SY, Doble B,
Lim TH, Aung ZW, Takano A, Tan WL, Ang MK, et al: Utility of
incorporating next-generation sequencing (NGS) in an Asian
non-small cell lung cancer (NSCLC) population: Incremental yield of
actionable alterations and cost-effectiveness analysis. Lung
Cancer. 139:207–215. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Heemskerk-Gerritsen BAM, Menke-Pluijmers
MBE, Jager A, Tilanus-Linthorst MM, Koppert LB, Obdeijn IM, van
Deurzen CH, Collée JM, Seynaeve C and Hooning MJ: Substantial
breast cancer risk reduction and potential survival benefit after
bilateral mastectomy when compared with surveillance in healthy
BRCA1 and BRCA2 mutation carriers: A prospective analysis. Ann
Oncol. 24:2029–2035. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mosele F, Remon J, Mateo J, Westphalen CB,
Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M,
Meric-Bernstam F, et al: Recommendations for the use of
next-generation sequencing (NGS) for patients with metastatic
cancers: A report from the ESMO precision medicine working group.
Ann Oncol. 31:1491–1505. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mateo J, Chakravarty D, Dienstmann R,
Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CK, Bedard PL,
Tortora G, Douillard JY, et al: A framework to rank genomic
alterations as targets for cancer precision medicine: The ESMO
scale for clinical actionability of molecular targets (ESCAT). Ann
Oncol. 29:1895–1902. 2018.PubMed/NCBI View Article : Google Scholar
|
